CFD
CLDX icon

Creative Financial Designs’s Celldex Therapeutics CLDX Stock Holding History

Creative Financial Designs’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-83
Closed -$2.82K – 1797
2024
Q3 		$2.82K Buy
+83
New +$3.16K ﹤0.01% 1489

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Creative Financial Designs's CLDX Position: Q4 2024 in Review

Creative Financial Designs sold out of Celldex Therapeutics (CLDX) in Q4 2024, closing a stake of 83 shares — an estimated $2.82K sold.

Creative Financial Designs first reported a position in CLDX in Q3 2024 and held it in 1 quarter. The position peaked at $2.82K in Q3 2024. 174 funds tracked by Wall St. Rank hold CLDX as of Q4 2024.

  • Creative Financial Designs reported no remaining Celldex Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Creative Financial Designs sold 83 Celldex Therapeutics shares in Q4 2024, an estimated $2.82K.
  • Creative Financial Designs first reported a position in Celldex Therapeutics in Q3 2024 and held it in 1 quarter.
  • Creative Financial Designs's Celldex Therapeutics position peaked at $2.82K in Q3 2024.
  • 174 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q4 2024.

Based on Creative Financial Designs's 13F filing for Q4 2024, filed 10 Feb 2025.